NY-BR-96: A Potential Drug Target for Breast Cancer (G92335)

Target Name: STRADA

NCBI ID: G92335

NY-BR-96: A Potential Drug Target for Breast Cancer

STRADA (Serologically defined breast cancer antigen NY-BR-96) is a protein that is expressed in the breasts and has been identified as a potential drug target for breast cancer. NY-BR-96 is a serially-linked monocistromeric protein that consists of 96 amino acids. It is expressed in the breasts tissue and has been shown to be associated with the development and progression of breast cancer.

One of the key findings of the study that identified NY-BR-96 as a potential drug target was that it was overexpressed in the breasts of breast cancer patients. This suggests that targeting NY-BR-96 may be an effective way to treat breast cancer.

In addition to its potential as a drug target, NY-BR-96 has also been identified as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective and less invasive.

In addition to its potential as a drug target, NY-BR-96 has also been shown to have potential as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective and less invasive.

In addition to its potential as a drug target, NY-BR-96 has also been shown to have potential as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The study that identified NY-BR-96 as a potential drug target for breast cancer was based on a combination of genetic and biochemical data. The researchers identified NY-BR-96 as they were analyzing the genomic profiles of breast cancer cells. They also used biochemical assays to confirm that NY-BR-96 was expressed in the breasts tissue.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective and less invasive.

In addition to its potential as a drug target, NY-BR-96 has also been shown to have potential as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The study that identified NY-BR-96 as a potential drug target for breast cancer was based on a combination of genetic and biochemical data. The researchers identified NY-BR-96 as they were analyzing the genomic profiles of breast cancer cells. They also used biochemical assays to confirm that NY-BR-96 was expressed in the breasts tissue.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective and less invasive.

In addition to its potential as a drug target, NY-BR-96 has also been shown to have potential as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The study that identified NY-BR-96 as a potential drug target for breast cancer was based on a combination of genetic and biochemical data. The researchers identified NY-BR-96 as they were analyzing the genomic profiles of breast cancer cells. They also used biochemical assays to confirm that NY-BR-96 was expressed in the breasts tissue.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective and less invasive.

In addition to its potential as a drug target, NY-BR-96 has also been shown to have potential as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The study that identified NY-BR-96 as a potential drug target for breast cancer was based on a combination of genetic and biochemical data. The researchers identified NY-BR-96 as they were analyzing the genomic profiles of breast cancer cells. They also used biochemical assays to confirm that NY-BR-96 was expressed in the breasts tissue.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective and less invasive.

In addition to its potential as a drug target, NY-BR-96 has also been shown to have potential as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The study that identified NY-BR-96 as a potential drug target for breast cancer was based on a combination of genetic and biochemical data. The researchers identified NY-BR-96 as they were analyzing the genomic profiles of breast cancer cells. They also used biochemical assays to confirm that NY-BR-96 was expressed in the breasts tissue.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective and less invasive.

In addition to its potential as a drug target, NY-BR-96 has also been shown to have potential as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The study that identified NY-BR-96 as a potential drug target for breast cancer was based on a combination of genetic and biochemical data. The researchers identified NY-BR-96 as they were analyzing the genomic profiles of breast cancer cells. They also used biochemical assays to confirm that NY-BR-96 was expressed in the breasts tissue.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective and less invasive.

In addition to its potential as a drug target, NY-BR-96 has also been shown to have potential as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The study that identified NY-BR-96 as a potential drug target for breast cancer was based on a combination of genetic and biochemical data. The researchers identified NY-BR-96 as they were analyzing the genomic profiles of breast cancer cells. They also used biochemical assays to confirm that NY-BR-96 was expressed in the breasts tissue.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective and less invasive.

In addition to its potential as a drug target, NY-BR-96 has also been shown to have potential as a biomarker for breast cancer. This means that it can be used as a diagnostic tool for breast cancer, particularly in cases where a biopsy is not possible.

The study that identified NY-BR-96 as a potential drug target for breast cancer was based on a combination of genetic and biochemical data. The researchers identified NY-BR-96 as they were analyzing the genomic profiles of breast cancer cells. They also used biochemical assays to confirm that NY-BR-96 was expressed in the breasts tissue.

The identification of NY-BR-96 as a potential drug target for breast cancer has implications for the treatment of this disease. Currently, there are few effective options for treating breast cancer, and the development of new drug targets can lead to the development of new treatments that are more effective

Protein Name: STE20 Related Adaptor Alpha

Functions: Pseudokinase which, in complex with CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta), binds to and activates STK11/LKB1. Adopts a closed conformation typical of active protein kinases and binds STK11/LKB1 as a pseudosubstrate, promoting conformational change of STK11/LKB1 in an active conformation

More Common Targets